Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Clinical and experimental studies suggest that bosentan could delay the progression of
interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for
which no established efficacious treatment is available. The present trial investigates a
possible use of oral bosentan, which is currently approved for the treatment of symptoms of
pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients
suffering from ILD associated with SSc.